<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040295</url>
  </required_header>
  <id_info>
    <org_study_id>B7981030</org_study_id>
    <nct_id>NCT05040295</nct_id>
  </id_info>
  <brief_title>A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSS-OVER, SINGLE DOSE STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF PEDIATRIC RITLECITINIB (PF-06651600) CAPSULES AND SPRAY CONGEALED BEADS RELATIVE TO ADULT CAPSULES IN HEALTHY ADULT PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I, single dose study to test two forms of pediatric ritlecitinib compared to adult&#xD;
      ritlecitinib in healthy adults aged 18-55 years old. Approximately 12 adults will participate&#xD;
      for approximately 2.5 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2021</start_date>
  <completion_date type="Anticipated">November 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time profile from time 0 extrapolated to infinite time (AUCinf) for ritlecitinib</measure>
    <time_frame>Day 1 pre-dose (hour 0) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16 and Day 2 at 24 hours post-dose in periods 1-3.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) for ritlecitinib</measure>
    <time_frame>Day 1 pre-dose (hour 0) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16 and Day 2 at 24 hours post-dose in periods 1-3.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant abnormalities in clinical laboratory values</measure>
    <time_frame>Baseline through Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (AEs)</measure>
    <time_frame>Baseline through Day 40</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment sequence 1 will receive a single 30 milligrams (mg) ritlecitinib intact adult capsule during the first period, three 10 mg ritlecitinib pediatric capsules during the second period and 30 mg ritlecitinib spray congealed beads in the third period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment sequence 2 will receive three 10 mg ritlecitinib pediatric capsules during the first period, a single 30 mg intact adult capsule during the second period and 30 mg ritlecitinib spray congealed beads in the third period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritlecitinib</intervention_name>
    <description>30 mg intact adult capsule</description>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritlecitinib</intervention_name>
    <description>10 mg pediatric capsule</description>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritlecitinib</intervention_name>
    <description>30 mg spray congealed beads</description>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female participants who are healthy as determined by medical evaluation&#xD;
             including a detailed medical history, complete (full) physical examination, which&#xD;
             includes BP and pulse rate measurement, clinical laboratory tests, and 12-lead ECG.&#xD;
&#xD;
          -  BMI of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological,&#xD;
             dermatological, or allergic disease (including drug allergies, but excluding&#xD;
             untreated, asymptomatic, seasonal allergies at the time of dosing).&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).&#xD;
&#xD;
          -  Known immunodeficiency disorder, including positive serology for HIV at screening, or&#xD;
             a first degree relative with a hereditary immunodeficiency&#xD;
&#xD;
          -  Infection with hepatitis B or hepatitis C viruses.&#xD;
&#xD;
          -  History of any lymphoproliferative disorder&#xD;
&#xD;
          -  Known present or a history of malignancy other than a successfully treated or excised&#xD;
             nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in&#xD;
             situ&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7981030</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

